Clinical Practice Guidelines for the management of locally advanced ...

45. Melton LJ, III, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H. Fracture risk
following bilateral orchiectomy. Journal of Urology 2003;169(5):1747-1750.
46. Janoff DM, Peterson C, Mongoue-Tchokote S et al. Clinical outcomes of androgen deprivation
as the sole therapy for localized and locally advanced prostate cancer. BJU International
2005;96(4):503-507.
47. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures
after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol
2006;175(1):136-139.
48. Smith MR. Therapy insight: Osteoporosis during hormone therapy for prostate cancer. Nature
Clinical Practice Urology 2005;2(12):Dec.
49. Dickman PW, Adolfsson J, Astrom K, Steineck G. Hip fractures in men with prostate cancer
treated with orchiectomy. Journal of Urology 172(6 Pt 1):2208-12, 2004.
50. Shahinian VB, Kuo Y, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation
for prostate cancer. New England Journal of Medicine 2005;352(2):154-164.
51. Krupski TL, Smith MR, Lee WC et al. Natural history of bone complications in men with
prostate carcinoma initiating androgen deprivation therapy.[erratum appears in Cancer. 2004
Nov 15;101(10):2370]. Cancer 2004;101(3):541-549.
52. Berruti A, Dogliotti L, Terrone C et al. Changes in bone mineral density, lean body mass and
fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer
without apparent bone metastases given androgen deprivation therapy. Journal of Urology
2002;167(6):2361-2367.
53. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA. Fracture risk in patients
with prostate cancer on androgen deprivation therapy. Osteoporosis International
2005;16(6):707-711.
54. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in
men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J
Urol 1999;161(4):1219-1222.
55. Townsend MF, Sanders WH, Northway RO, Graham SD, Jr. Bone fractures associated with
luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma.
Cancer 1997;79(3):545-550.
56. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing
hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.
J Clin Endocrinol Metab 2004;89(8):3841-3846.
57. Iversen P, Tyrrell CJ, Kaisary AV et al. Casodex (bicalutamide) 150-mg monotherapy
compared with castration in patients with previously untreated nonmetastatic prostate cancer:
results from two multicenter randomized trials at a median follow-up of 4 years. Urology
51(3):389-96, 1998.
58. Iversen P. Quality of life issues relating to endocrine treatment options. European Urology Vol
36 1999;Suppl. 2:20-26.
59. Green HJ, Pakenham KI, Headley BC, Gardiner RA. Coping and health-related quality of life
in men with prostate cancer randomly assigned to hormonal medication or close monitoring.
Psycho-Oncology 11(5):401-14, 2002;-Oct.
60. Boccardo F, Rubagotti A, Barichello M et al. Bicalutamide monotherapy versus flutamide plus
goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. Journal
of Clinical Oncology 17(7):2027-38, 1999.
43
Locally advanced disease